Floatz logo

Milatuzumab

Diffuse Large B-cell Lymphoma

Gilead Sciencesmonoclonal_antibodyPhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
73/ 100

Competitive context

29 Active assets in the Diffuse Large B-cell Lymphoma cohort.

Asset / SponsorPhaseRating
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Mwanasha Merrill, MD
Phase 4BB
Tucidinostat
Rong Tao
Phase 3BB
Zilovertamab Vedotin
Merck Sharp & Dohme LLC
Phase 3BB
Everolimus
University of California, Davis
Phase 3BB
Tafasitamab
Brown University
Phase 3BB

View all 50 →

Same molecule, other indications

Milatuzumab is also rated in:

NHLDormant
B
Indicative ·
58 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CCC
Indicative ·
52 / 100
View asset →
Lymphoma, Large-CellDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →